NEW YORK (360Dx) – The World Health Organization has deemed interferon gamma-release assays (IGRAs) an appropriate alternative to the tuberculin skin test (TST) for determining which patients in regions with a high disease burden may progress to active tuberculosis.

WHO issued the recommendation this week as part of broader guidelines for the diagnosis, treatment, and management of latent TB. The new recommendation is a positive for Qiagen and Oxford Immunotec, both of which market IGRAs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Sponsored by

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.